FindMyKOL

James Lewis

Enriched profile

Gastroenterology

ORCIDNone on fileNPI↗
✓ Itemized profile
RegionWashington, DC · NortheastSpecialtyGastroenterologyFocusGastroenterology
Active KOLFindMyKOL type: EliteLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding1987–2007Why? →

James Lewis is a Gastroenterology physician.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
0clinical trials

Investigator role on registered studies.

View trials ↓
37companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
3NIH grants · 1987–2007

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →

Industry payments

37 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    72.8%
    Nucleoside and nucleotide reverse transcriptase inhibitors72.8%
    Vemlidy63%Tenofovir Disoproxil Fumarate37%
    Part D<11 patients
  • Metabolism & gastrointestinal

    27.2%
    Rifamycin Antibacterial13.6%
    Xifaxan100%
    Part D<11 patients
    Bile Acid13.6%
    Ursodiol100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

3 NIH research awards on record, funded 1987–2007 per NIH RePORTER. The latest:

3 awards on record per NIH RePORTER; the itemized rows are on their way. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Similar KOLs

Other experts from the same institution or the same specialty.